DVA
DaVita Inc.
DVA has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over DVA overall, supported by stronger fundamentals and stronger modeled upside.
DVA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Under pressure |
DVA's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $174 | — |
| Cheap | 12x | $166 | -4.7% |
| Current | 13x | $174 | — |
| Fair | 15x | $202 | +16% |
| Expensive | 18x | $243 | +40% |
Historical ranges are pointers, not guarantees.
DVA has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DVA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DVA's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over DVA on the outlook, with more favorable revenue expectations.
DVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $16.10 | +19% |
| Q3 2026 | $13.51 | +39% |
| Q2 2026 | $12.15 | +20% |
| Q1 2026 | $10.71 | +6.3% |
| Q4 2025 | $9.84 | -8.3% |
| Q3 2025 | $9.70 | +4.4% |
| Q2 2025 | $10.16 | +8% |
| Q1 2025 | $10.08 | +14% |
| Q4 2024 | $10.73 | +45% |
DVA earned $13.51 per share over the past year, up 39% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DVA on earnings, with more consistent year-over-year improvement.
DVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.6B | +4.6% |
| Q2 2026 | $3.6B | +5.2% |
| Q1 2026 | $3.4B | +6% |
| Q4 2025 | $3.6B | +9.9% |
| Q3 2025 | $3.4B | +4.8% |
| Q2 2025 | $3.4B | +6.1% |
| Q1 2025 | $3.2B | +5% |
| Q4 2024 | $3.3B | +4.7% |
DVA's revenue has grown year over year for 15 quarters in a row: $3.6B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -0.8 points |
| Q2 2026 | 16% | +0.4 points |
| Q1 2026 | 14% | +0.5 points |
| Q4 2025 | 16% | -1.7 points |
| Q3 2025 | 15% | -1.6 points |
| Q2 2025 | 16% | 0 points |
| Q1 2025 | 14% | -2.1 points |
| Q4 2024 | 17% | +4.8 points |
DVA's operating margin was 14% last quarter, down 0.8 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DVA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DVA on profitability, with a higher operating margin.
DVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $359.3M | -47% |
| Q2 2026 | $320.3M | +58% |
| Q1 2026 | $218.8M | +495% |
| Q4 2025 | $395.3M | +4.9% |
| Q3 2025 | $675.4M | +0.6% |
| Q2 2025 | $203.1M | -70% |
| Q1 2025 | $36.8M | +$292.6M |
| Q4 2024 | $377M | +16% |
DVA generated $1.3B in free cash flow over the past year, about the same as the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
DVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -588K shares |
| 1 year | -11% | -8.3M shares |
| 3 years | -30% | -28.5M shares |
| 5 years | -40% | -44.3M shares |
| Available history | -57% | -88.3M shares |
DVA has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $73M |
| Q2 2026 | $181.5M |
| Q1 2026 | $196.4M |
| Q4 2025 | $274.5M |
| Q3 2025 | $240.1M |
| Q2 2025 | $283.7M |
| Q1 2025 | $510.2M |
| Q4 2024 | $365.4M |
DVA spent $725M buying back its own shares over the past year, down 48% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q2 2026 | 3.6x | Elevated |
| Q1 2026 | 3.6x | Elevated |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.4x | Elevated |
| Q1 2025 | 3.4x | Elevated |
| Q4 2024 | 3.1x | Elevated |
DVA's net debt is about 3.6 years of its operating earnings (EBITDA), up from 3.5 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over DVA on leverage, with a lower net debt burden relative to earnings.
DVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 19.8 | Oversold |
DVA's weekly RSI is 44 (neutral) and its Stochastic is 20 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DVA PE vs Healthcare Sector
| Metric | DVA | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 26 | 29 | 3 pts below |
DVA has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $182.5 | 4.6% below |
| 20 week MA | $195.4 | 11% below |
| 50 week MA | $169.8 | 2.5% above |
| 100 week MA | $155.7 | 12% above |
| 200 week MA | $136.0 | 28% above |
DVA has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 28% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DVA on trend strength, trading above more of its moving averages.
DVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.8 | $115.1 | +54% |
| 2021 | $115.1 | $111.4 | -3.2% |
| 2022 | $111.4 | $73.8 | -34% |
| 2023 | $73.8 | $104.8 | +42% |
| 2024 | $104.8 | $154.3 | +47% |
| 2025 | $154.3 | $114.0 | -26% |
| 2026 YTD | $114.0 | $174.1 | +53% |
DVA has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.